Define_*.

[Journal of Clinical Oncology @JCO_ASCO]

‼️ #ASCO26 simultaneous publication by Mascarenhas et al:

Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial

Read the full article: https://t.co/qlwEwILG3x

[Dr Rishabh Jain @DrRishabhOnco]

🩸 THE 10 MOST IMPORTANT MALIGNANT HEMATOLOGY TRIALS OF #ASCO26

🧬 LEUKEMIA, MDS & MYELOID MALIGNANCIES

1️⃣ SENTRY (LBA6500)
Selinexor + ruxolitinib vs ruxolitinib in frontline myelofibrosis
Can XPO1 inhibition improve survival beyond spleen responses?

2️⃣ COMMANDS 3-Year Update (6566)
Luspatercept vs epoetin alfa in lower-risk MDS
Does early transfusion independence alter long-term outcomes?

3️⃣ IDH1 Triplet Platform (6503)
Azacitidine + venetoclax + ivosidenib in IDH1-mutated AML
MRD-negative frontline AML strategies continue evolving.

4️⃣ Revumenib Post-SCT Maintenance (6505)
Menin inhibition after transplant in KMT2A/NPM1 AML
Targeted relapse prevention enters center stage.

5️⃣ Quizartinib Triplet Combo (6504)
Quizartinib + decitabine + venetoclax
Aggressive FLT3 resistance targeting strategy.

🧠 LYMPHOMA & CLL

6️⃣ frontMIND (LBA7000)
Tafasitamab + lenalidomide + R-CHOP in frontline DLBCL
A major frontline escalation study.

7️⃣ CONQUER (6508)
Dual-epitope anti-CD5 nanobody CAR-T in T-cell malignancies
Novel engineering approaches attempt to solve CAR-T fratricide.

💥 MULTIPLE MYELOMA & PLASMA CELL DISORDERS

8️⃣ DREAMM-9 Final Analysis (7503)
Belantamab mafodotin + VRd in transplant-ineligible NDMM
One of the biggest myeloma presentations at ASCO26.

9️⃣ MajesTEC-9 (LBA7507)
Teclistamab vs standard triplets in relapsed/refractory myeloma
Bispecifics continue moving earlier.

🔟 SUCCESSOR-2 (LBA7506)
Sequencing BCMA vs GPRC5D bispecifics
Critical real-world sequencing question.

#HemOnc #OncTwitter #ASCO26 #Leukemia #Lymphoma #Myeloma #MedTwitter @ASCO @myesmo @esmo_open @OncoAlert @Larvol

[Define_*. @pec_panco_Alex]

@Komatinsky21199 That’s what I heard from several physicians from Taiwan. There is no practical guideline in using MPN-10 or TSS in real world, it’s not an objective indicator. They only focus on the spleen shrinkage, and they all said any single jak1/2 inhibitor can’t met the needs.

[Define_*. @pec_panco_Alex]

https://t.co/7Z2RZlA3cm

[Define_*. @pec_panco_Alex]

@tetonbio https://t.co/7Z2RZlA3cm

[Define_*. @pec_panco_Alex]

@sak77328 @Papa_Heme @VPrasadMDMPH Papa responded. You win.😂

[Define_*. @pec_panco_Alex]

@Papa_Heme @sak77328 @VPrasadMDMPH https://t.co/dqHSJc2OoZ

[Define_*. @pec_panco_Alex]

@pan_accindex @Papa_Heme @VPrasadMDMPH 好噁心的圖

[MPN_Hub @MPN_Hub]

In our latest podcast, Jean-Jacques Kiladjian discusses the key findings from the 12-month primary endpoint analysis of the ROP-ET phase III study, presented at #ASH25.

Listen here: https://t.co/izE6Uv7urt

#MPN #EssentialThrombocythemia #MPNsm #MedEd @jjkiladjian

[MPN_Hub @MPN_Hub]

CONGRESS | #ASH2025 | POSTER

Tiziano Barbui shares real-world findings from a cohort of a prospective, non-interventional, post-authorization study (ROPEG-PV), evaluating ropeginterferon alfa-2b (Ropeg) in patients with polycythemia vera (N = 316).

Hematologic response rates improved from 17.9% at baseline to 50.0% at 24 months, with phlebotomy need also declining. Thrombotic events (n=7), disease progression (n=9), secondary cancer (n=3), and deaths (n=3) were infrequent. A total of 88 AEs were reported, including 12 Grade 3–5 events, with SAEs uncommon. Treatment discontinuation reached 20.9% and 31.8% at 12 months and 24 months, respectively.

Follow our live feed for more updates: https://t.co/Z99bijEUG4

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.

#MPN #MPNsm #PolycythemiaVera #MedEd #MedicalCongress @FromBergamo

[Daniel Auclair @AuclairDan]

Sitting here at #ASH25 , I am blown away by the progress in #myeloma in the 21st century. I never thought we could “cure” patients from MM in my lifetime. When I started in the field a quarter century ago, patients would be lucky to make it past 3 years post-diagnosis #mmsm

[MPN_Hub @MPN_Hub]

CONGRESS | #ASH25 | PRESENTATION

Jean-Jacques Kiladjian presents 12-month primary endpoint analysis from the ROP-ET phase 3 study of ropeginterferon alfa-2b in patients with essential thrombocytopenia (N = 132).

The study met its primary endpoint, 48.0% showed a durable disease response. 62.3% of patients experienced symptom improvement, 25.4% had no disease progression.
Safety profile was in live with the experience in PV. TRAEs were mostly mild in 68.9% of patients. Grade ≥3 TRAEs reported in 5.3%. Most common AEs were ALT increase, headache, neutropenia and pruritus.

Follow our live feed for more updates: https://t.co/Z99bijEUG4
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#MPN #MPNsm #MedEd #MedicalCongress @jjkiladjian @APHP @Univ_Paris

[Define_*. @pec_panco_Alex]

@MPN_Hub What about white / plt count

[Define_*. @pec_panco_Alex]

@AceTaiwan 請問中國人要怎麼投票🤣🤣

[Define_*. @pec_panco_Alex]

@Papa_Heme It’s time for patients’ rights. Not defined by any PAPA.

[Define_*. @pec_panco_Alex]

@kinatsofrim @Papa_Heme @jmikhaelmd @khouri_jack @Myeloma_Doc @JoshuaRichterMD @BiranNoa @BerdejaJesus @JKaufmanMD @TomBmt133 @WexCapital My cousin was saved by selinexor. Thanks for the drug. And please don’t deprive the rights of receiving appropriate treatment. My mom died because of GBM, and I hope this drug will help GBM patients.

[Define_*. @pec_panco_Alex]

@hsgxxxxx 懶叫比雞腿

[Define_*. @pec_panco_Alex]

@ltntw 他不知道死了幾隻猴子 但台中盧大嬸可以不要再加測速照相了嗎

[Define_*. @pec_panco_Alex]

@zhe_wang71411 開始要組市民自衛軍了

[David Scott Miller @dsmgyo]

The long-term results of the #SIENDO, @GOG 3055, trial presented at #IGCS2025. Awaiting the completion of the #XPORT, @GOG 3083 trial of #Selinexor in #EndometrialCancer. Open at @utswcancer & @Parkland.

#gyncsm #clinicaltrial @XPOVIOHCP